pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,225 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1068Endpoints809BioPharma Dive311BioSpace240Fierce Biotech228onclive165raps86globenewswire health
therapy area
allOncology6396Rare Disease1520Cardiology1208Hematology1092Immunology1073Vaccines965Pulmonology
  • 26 states file lawsuit to halt federal Medicaid work-requirement rule
    Five New England states joined 21 others in a lawsuit filed Monday to stop a federal rule that would add work requirements to Medicaid. The states argue the new guidelines create an unfair bureaucr…
    STAT · 1mo agoRegulatoryNegative↗ source
  • FDA adds peptide-focused physicians to advisory panel, raising conflict-of-interest concerns
    The FDA announced eight new members for a committee that will advise on whether compounding pharmacies can produce certain peptides. Most of the appointees are physicians or pharmacists who run bu…
    STAT · 1mo agoRegulatoryNegative↗ source
← prev
page 53 of 89
next →
73
fda recalls54
fda medwatch47
fda press30
940
Psychiatry & CNS757
Ophthalmology455
Pain424
Endocrinology & Metabolism402
Infectious Disease380
  • Zymeworks CEO says $1 billion Theravance acquisition offers strong value despite recent setbacks
    Zymeworks chief executive Kenneth Galbraith explained why the company believes its near-$1 billion purchase of Theravance makes strategic sense. He noted that Theravance has faced operational diff…
    Endpoints · 1mo agoDealPositive↗ source
  • Evommune's lead drug fails in chronic hives trial, shares tumble over 30%
    Evommune reported its first major trial readout since going public last year, focusing on its lead candidate for chronic spontaneous urticaria, a condition where patients experience recurring hives…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • Talawar Therapeutics merges with JATT II Acquisition to list on Nasdaq as AstraZeneca reports Phase 3 success in pediatric bone disease
    Talawar Therapeutics announced a combination with blank‑check company JATT II Acquisition Corp, a deal that will place Talawar on the Nasdaq exchange. The SPAC transaction gives Talawar public‑mar…
    Endpoints · 1mo agoDealPositive↗ source
  • Chinese partnerships are becoming the pharma industry's new tax inversion strategy
    The article notes that a decade after the wave of U.S. tax inversions, the pharmaceutical sector is now seeing a similar pattern with deals involving Chinese entities. Analysts argue that these tra…
    Endpoints · 1mo agoDealNeutral↗ source
  • Ipsen to acquire blood-cancer specialist Kartos Therapeutics for $450 million upfront
    Ipsen announced it will purchase Kartos Therapeutics, a company focused on blood cancers. The transaction includes a $450 million cash payment at closing, with the possibility of up to $1.75 billi…
    Endpoints · 1mo agoDealPositive↗ source
  • BioCryst to shut internal drug discovery and close Alabama research site
    BioCryst Pharmaceuticals announced it is winding down its internal drug discovery efforts. The company said it will seek future programs through external collaborations rather than in‑house resear…
    Endpoints · 1mo agoNegative↗ source
  • 5 takeaways from STAT’s investigation into microhospital operator Nutex Health
    Read the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.
    STAT · 1mo agoRegulatoryNeutral↗ source
  • FDA’s top gene-therapy regulator Vijay Kumar steps down amid leadership shake-up
    Vijay Kumar, the acting director of the FDA office that reviews cell and gene therapies, has announced he will leave his position. In an email to staff, Kumar said he reflected on his tenure and de…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • AstraZeneca to Pay $34 Million Settlement Over Texas Medicaid Kickback Allegations
    AstraZeneca has agreed to a $34 million settlement with the Texas attorney general over allegations that it provided improper incentives to boost prescriptions covered by Texas Medicaid. The state…
    STAT · 1mo agoRegulatoryNegative↗ source
  • J&J EVP John Reed Discusses R&D Model, Oncology Deals and Pipeline Growth Potential
    John Reed, executive vice president of Innovative Medicine at Johnson & Johnson, brings more than a decade of experience overseeing drug pipelines at three of the world’s largest pharmaceutical com…
    Endpoints · 1mo agoNeutral↗ source
  • Over 200 biopharma investors urge EU governments to strengthen Europe's life-science sector
    More than 200 biopharma investors and companies have signed an open letter addressed to EU member states, calling for action to improve Europe's life‑science sector. The signatories argue that Eur…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • California hospital lawsuits reveal forced McKinsey ties and surprise ER chain profits
    Unredacted comments from recent California hospital lawsuits show that hospital executives admitted to a "forced" partnership with consulting firm McKinsey, raising questions about the influence of…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Precision strategies help de-risk rare disease therapy launches
    Commercializing a rare disease therapy presents a high‑risk, high‑reward scenario for biotech firms. Small patient populations, stringent regulatory requirements, and the need to sustain value beyo…
    Fierce Biotech · 2mo agoNeutral↗ source
  • Endpoints News celebrates ten years of bootstrapped growth and a 50/50 founder partnership
    John Carroll and Arsalan Arif launched Endpoints News a decade ago with no seed funding or investors, describing themselves as completely broke. They built the news service from scratch, relying on…
    Endpoints · 2mo agoPositive↗ source
  • STAT readers split on spelling of "health care" as industry leans toward single word
    STAT recently asked its audience whether to write the term as two words or one. Roughly 60% of respondents favored one spelling over the other. The discussion highlights a subtle but growing trend…
    STAT · 2mo agoNeutral↗ source
  • STAT invites reader debate on blue zones and open-access publishing fees
    Torie Bosch, editor of STAT’s First Opinion platform, has published an opinion piece encouraging readers to submit letters responding to recent essays. The article explains that STAT will publish…
    STAT · 2mo agoNeutral↗ source
  • Weekly roundup highlights LGBTQ+ leadership in biopharma and reports of a Novo Nordisk hack
    The latest Endpoints Weekly newsletter was published on June 20, 2026, coinciding with the summer solstice in the northern hemisphere. The issue spotlights the growing visibility of LGBTQ+ leaders…
    Endpoints · 2mo agoNeutral↗ source
  • Daraxonrasib doubles median survival in pancreatic cancer trial, FDA grants early access
    An international study presented at the American Society of Clinical Oncology meeting in Chicago showed that patients with pancreatic cancer who received daraxonrasib lived an average of 13.2 month…
    STAT · 2mo agoPositive readoutPositive↗ source
  • US launches trade probe into Germany's plan to lower drug prices
    US Department of Commerce announced on June 19, 2026 that it has opened a Section 301 trade investigation targeting Germany’s drug pricing system. The probe follows Germany’s ongoing review of its…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • Tennessee pharmacies sell high-strength ivermectin under anti-vaccine doctor's direction
    Tennessee pharmacies have begun offering high-strength formulations of the antiparasitic drug ivermectin. The sales are being led by a physician known for anti-vaccine views, who has publicly said…
    STAT · 2mo agoNegative↗ source
  • Rural U.S. faces growing maternity care deserts despite falling fertility rates
    Pregnant women in many rural parts of the United States often must travel two hours or more to reach a hospital that can deliver a baby, putting them at risk if labor starts early or complications…
    STAT · 2mo agoNegative↗ source
  • Federal grant delays threaten disability research and services
    Grants from the National Institute on Disability, Independent Living, and Rehabilitation Research have been postponed by several months, leaving researchers uncertain about funding. The delays are…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Protego Biopharma appoints Jae Kim as chief medical officer
    Protego Biopharma announced the addition of Jae Kim to its executive team as chief medical officer. Kim comes to Protego after serving as chief medical officer at both Septerna and Design Therapeu…
    STAT · 2mo agoNeutral↗ source